Compositions targeting cancer antigens and methods of use thereof
Antibodies and bispecific T cell engagers targeting cancer antigens like TAS2R13, TMEM191C, and ADAM20 provide effective cancer treatments by killing tumor cells and reducing symptoms through targeted immune responses.
WO2025235413A1 Publication Date: 2025-11-13DUKE UNIV
7 Cites 0 Cited by
Patent Information
- Application Number
- PCT/US2025/027818
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-05-05
- Filing Date
- 2025-05-05
- Publication Date
- 2025-11-13
AI Technical Summary
Technical Problem
Current cancer treatments lack effective therapies that target cancer-specific markers, such as antibodies, antibody drug conjugates, and bispecific T cell engagers, which are highly desirable for more precise and targeted approaches.
Method used
Development of antibodies and antibody drug conjugates that specifically target cancer antigens like TAS2R13, TMEM191C, and ADAM20, as well as bispecific T cell engagers to redirect cytotoxic T cells to cancer cells, utilizing IgG and dimeric IgA antibodies with cytotoxic and/or inhibitory activity.
Benefits of technology
These compositions effectively treat cancer by killing tumor cells, slowing disease progression, and attenuating or eliminating cancer symptoms through targeted immune responses.
✦ Generated by Eureka AI based on patent content.
Abstract
Disclosed herein are antibodies, antibody drug conjugates, and bispecific T cell engagers targeting TAS2R13, TMEM191C, ADAM20, or any combination thereof on the surface of cancer cells. Also disclosed are methods of using these compositions to treat cancer and / or slowing disease progression in a subject.
Need to check novelty before this filing date? Find Prior Art